Model of the equine rhinitis A virus capsid: identification of a major neutralizing immunogenic site.

The research article focuses on identifying the primary immunogenic site of the Equine Rhinitis A Virus (ERAV) through the use and experimentation with mouse monoclonal antibodies. Constructing a capsid model and manipulating its structural components allowed researchers to propose how ERAV’s immunogenic site is formed, aiming to expand the understanding of the virus and aid in potential vaccine development.

Use of Monoclonal Antibodies

• The research began by the employment of mouse monoclonal antibodies (mAbs) to select ERAV mutants that could escape normalization.
• This approach led to the identification of amino acid alterations, specifically at VP1’s Lys-114, Pro-240, and Thr-241 positions, that resulted in resistance to neutralization.

Immunogenic Site Identification

• Despite the identified changes scattering across different sections of the polypeptide chain, the mutants showcased cross-resistance against all the mAbs, indicating that the residues contribute to a singular immunogenic site.
• This prompted the researchers to elaborate on the ERAV’s structural model to explain their observations.

Capsid Model Construction

• The construction of a three-dimensional capsid model was introduced to better comprehend the observed resistance of the mutants. Investigators based their model on the closely-related Foot-and-Mouth Disease Virus (FMDV O1).
• According to the model, the VP1 protein’s arrangement places the Lys-114 in the beta E-beta F loop of the chain, a significant distance away from the Pro-240 and Trp-241 that come later in the C-terminal region.

Proposed Immunogenic Formation

• The research proposes that the VP1 in each protomer reaches the beta E-beta F loop of the adjacent VP1 at the five-fold axis of symmetry. The result is the proximity of Lys-114 residue in one VP1 molecule and the Pro-240/Thr-241 residues in the adjacent VP1 polypeptide chain.
• Through this arrangement, the formation of the immunogenic site in ERAV is suggested. When considered in the overall architecture of the viral capsid structure, this site closely correlates with the immunogenic site 1 of FMDV O1.

Implications of the Study

• The study’s findings help provide insight into the structure and behavior of ERAV, which can be utilized in better diagnosing, treating, and potentially preventing the virus via vaccine development.
• Moreover, the research also enhances the understanding of virus structures and functions, contributing to the field of virology.